MAPREG is a privately held company.
Present shareholders include its founders, business angels and institutionals.
To date MAPREG has raised a total 9,5 milions Euros equity with a 100% leverage effect (about 9 millions Euros of research supports among which OSEO/BPI, US Army, Eureka/European Grant and Credit Impot Recherche).
MAPREG is currently opening a B round for financing Phase 2 in Resistant Depression to be launched in late 2017
OSEO (now called BPI), the French public bank for innovation, granted 2 successive financial supports to help MAPREG complete the preclinical package of its lead compound.
The US ARMY supported the proof of concept in Traumatic brain Injuries with two successive grants.
The EUROPEAN COMMUNITY ranked our DEPSTER project 6th out of all competitive application. Thanks to this grant we made the proof that our drug candidate is a novel-, safe-, fast-acting antidepressant drug.
CHU Bicêtre, Batiment Pincus, 80 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France.